Voriconazole-d3
(Synonyms: VRC-d3) 目录号 : GC48254具有多种生物活性的神经肽
Cas No.:1217661-14-7
Sample solution is provided at 25 µL, 10mM.
Voriconazole-d3 is intended for use as an internal standard for the quantification of voriconazole by GC- or LC-MS. Voriconazole is a triazole antifungal agent and a derivative of fluconazole .[1],[2] It is active against a variety of yeast and fungi, including clinical isolates of A. flavus, A. fumigatus, F. oxysporum, F. solani, C. albicans, and C. neoformans (MICs = 1 Voriconazole is also active against 56 clinical isolates of fluconazole-resistant C. albicans (MICs = 0.015-8 µg/ml).[2] It inhibits ergosterol biosynthesis in C. albicans, C. glabrata, A. fumigatus, and A. flavus (IC50s = 0.03-1 µg/ml).[3] Voriconazole (10 mg/kg twice per day, i.v.) decreases the number of lung colony-forming units (CFUs), reduces alveolar collapse and lung inflammatory cell infiltration and necrosis, and increases survival in a rat model of invasive pulmonary aspergillosis.[4] Formulations containing voriconazole have been used in the treatment of fungal infections.
Reference:
[1].Espinel-Ingroff, A.In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogensJ. Clin. Microbiol.36(1)198-202(1998)
[2].Cuenca-Estrella, M., DÍaz-Guerra, T.M., Mellado, E., et al.Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from SpainEur. J. Clin. Microbiol. Infect. Dis.18(6)432-435(1999)
[3].Munayyer, H.K., Mann, P.A., Chau, A.S., et al.Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and moldsAntimicrob. Agents Chemother.48(10)3690-3696(2004)
[4].Zhang, M., Su, X., Sun, W.-K., et al.Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus speciesMycopathologia177(1-2)11-18(2014)
Cas No. | 1217661-14-7 | SDF | |
别名 | VRC-d3 | ||
化学名 | (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-4,4,4-d3-2-ol | ||
Canonical SMILES | FC1=CN=CN=C1[C@@H]([C@](O)(CN2N=CN=C2)C3=C(C=C(C=C3)F)F)C([2H])([2H])[2H] | ||
分子式 | C16H11D3F3N5O | 分子量 | 352.3 |
溶解度 | DMSO: 20 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.8385 mL | 14.1924 mL | 28.3849 mL |
5 mM | 0.5677 mL | 2.8385 mL | 5.677 mL |
10 mM | 0.2838 mL | 1.4192 mL | 2.8385 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet